Relmada Therapeutics Secures Key Presentation on NDV-01
Discover the 6-month follow-up from the ongoing Phase 2 trial designed to treat patients with non-muscle invasive bladder cancer (NMIBC).
With plans to further develop NDV-01—a sustained release intra-vesicular formulation of gemcitabine/docetaxel—into Phase 3 studies by mid-2026.
The focus targets high-risk NMIBC and intermediate-risk NMIBC, which together account for a substantial portion of annual NMIBC cases.
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a forward-looking clinical-stage biotechnology company dedicated to advancing therapies for oncology and central nervous system disorders, has exciting news to share. The company is preparing to showcase the significant findings from their ongoing Phase 2 study of NDV-01, particularly concentrating on the 6-month follow-up data at the Society of Urologic Oncology 26th Annual Meeting. The presentation will highlight the continuing efforts to transform the treatment landscape for NMIBC.
Dashboard of Phase 2 Study Results
Presented by Dr. Yair Lotan, Chairman of the Clinical Advisory Board at Relmada, the poster will detail essential insights pertinent to NDV-01, an innovative, sustained release treatment that integrates gemcitabine and docetaxel as a pivotal combination. This data reveals a favorable safety profile and appears to show strong efficacy in ongoing therapeutic applications.
Raj S. Pruthi, MD, Chief Medical Officer-Oncology at Relmada, expressed optimism regarding the findings, indicating that NDV-01 has the potential to deliver a transformational approach to NMIBC treatment. Emphasizing safety, convenience, and efficacy, NDV-01 is geared to offer both patients and physicians access to a ready-to-use, bladder-sparing therapeutic option that is clinically promising.
Society of Urologic Oncology Meeting Details
The poster’s details are being looked forward to by the medical community, and it bears the following critical information:
- Title: Prospective Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Sustained-Release Gemcitabine Docetaxel combination (NDV-01) in High-Risk NMIBC: Update with 6-month Complete Response Data
- Poster Number: #143
- Date and Time: December 4, at 2:30 PM MT
After the presentation, a copy of the poster will be available in the Events section of the Relmada website, where interested parties can delve deeper into the displayed findings and associated discussions with regulatory bodies.
Overview of NDV-01
NDV-01 is designed to be effective for treating non-muscle invasive bladder cancer by allowing a gradual release of gemcitabine and docetaxel over an extended period. This sustained-release formulation is unique in its design, allowing for better drug retention within the bladder and minimizing adverse systemic effects.
The administration process is straightforward—able to be completed in under ten minutes without the need for anesthesia or specialized equipment, thus enhancing its appeal for clinics and patients alike. The innovative nature of NDV-01 ensures that it remains patent-protected until 2038, paving the way for a robust treatment future.
Significance of the Phase 2 Study
This Phase 2 study employs a single-arm, open-label design and evaluates the safety and efficacy of NDV-01 among patients diagnosed with high-grade non-muscle invasive bladder cancer. Participants engage in a biweekly induction phase followed by monthly maintenance doses over a year, supported by thorough assessments.
The insightful results gathered thus far focus on both the safety of the treatment and overall response rates, with secondary endpoints exploring duration of response and event-free survival outcomes.
The NMIBC Context and Market Potential
NMIBC accounts for a significant percentage of bladder cancer cases, possessing high recurrence rates and limited treatment options for patients. With over 744,000 active cases nationwide, there exists a substantial opportunity for treatments like NDV-01 to fill existing gaps in the market.
By targeting high-risk and intermediate-risk cases, NDV-01 may serve as either a frontline or salvage therapy, offering hope across various NMIBC subtypes. The potential for NDV-01 exemplifies Relmada's commitment to developing comprehensive oncology solutions.
About Relmada Therapeutics
Relmada Therapeutics stands at the forefront of clinical innovation in biotechnology, with a focused strategy to pioneer groundbreaking therapies for both oncology and central nervous system disorders. Their lead candidates, including NDV-01, showcase an unwavering drive to meet significant patient needs in the current therapeutic landscape.
For further information regarding Relmada and its offerings, you can navigate to their official website.
Frequently Asked Questions
What is NDV-01?
NDV-01 is an innovative treatment being developed for non-muscle invasive bladder cancer, utilizing a sustained release formulation of gemcitabine and docetaxel.
What are the upcoming developments for Relmada Therapeutics?
Relmada plans to enter Phase 3 studies for NDV-01 in the first half of 2026, targeting NMIBC treatments.
Why is NMIBC significant?
Non-muscle invasive bladder cancer comprises a large portion of bladder cancer cases and is associated with high recurrence rates, necessitating effective treatment options.
How does NDV-01 improve treatment delivery?
NDV-01 enables gradual drug release and can be administered in a simple clinic visit without extensive equipment, enhancing patient comfort and compliance.
Where can I obtain more information about Relmada?
More detailed information is available on Relmada’s official website, showcasing their pipeline and clinical developments.
